13F Pro quality score
Rank #2,757 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Lunai Bioworks Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2026 | 10-K | $52.0K | $-3.6M | — |
| FY 2016 | 10-K | $42.8K | $-1.7M | — |
| FY 2013 | 10-Q | $32.8K | $-2.1M | — |
| FY 2012 | 10-Q | $62.8K | $-2.4M | — |
Lunai Bioworks Inc. (LNAI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LNAI at 19.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,757 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q4 2026), Lunai Bioworks Inc. reports quarterly revenue of $31.1K, net income of $-2.0M, free cash flow of $-1.8M. Top institutional holders of LNAI by reported 13-F value include Ground Swell Capital, STATE STREET, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. LNAI trades on the Nasdaq exchange and files with the SEC under CIK 1527728. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LNAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lunai Bioworks Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1527728 →